| Focus V (anlotinib) / Advenchen, Sino Biopharm |
| Ongoing | 1b | 30 | China | benmelstobart (APL-502) - Apollomics, Focus V (anlotinib) - Advenchen, Sino Biopharm | Nanjing Shunxin Pharmaceutical Co., Ltd./ Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Advanced soft tissue sarcoma | | | | |
NCT04012619: Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer |
|
|
| Completed | 1 | 8 | RoW | Anlotinib Hydrochloride, Pemetrexed,cisplatin/carboplatin | Sichuan University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-squamous Non-small-cell Lung Cancer, Anlotinib | 11/19 | 12/20 | | |
ChiCTR1900020704: A clinical study for Anlotinib combined with Platinum based dual drug concurrent radiotherapy for unresectable advanced non-small cell lung cancer |
|
|
| Not yet recruiting | 1 | 24 | | concurrent chemoradiotherapy combined with anlotinb 8mg ;concurrent chemoradiotherapy combined with anlotinb 10mg ;concurrent chemoradiotherapy combined with anlotinb 12mg ;concurrent chemoradiotherapy | The Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Xi'an Jiaotong University, Beijing medical and health foundation | lung cancer | | | | |
ChiCTR1800017929: Phase I-II clinical study for anlotinib in the treatment of brain metastases of non-small cell lung cancer |
|
|
| Recruiting | 1 | 20 | | anlotinib | Peking University Third Hospital; Peking University Third Hospital, The key clinical specialist research fund of Peking University Third Hospital | none small cell lung cancer | | | | |
NCT03910270: Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer |
|
|
| Not yet recruiting | 1 | 30 | NA | TQB2450, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Lung Cancer | 10/20 | 12/20 | | |
NCT04882033: Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 9 | RoW | Concurrent chemoradiotherapy plus anlotinib | Tianjin Medical University Cancer Institute and Hospital | Small Cell Lung Cancer Limited Stage | 07/21 | 07/23 | | |
NCT04764084: Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 52 | RoW | Niraparib, Zejula, Anlotinib | Beijing Cancer Hospital | HER2-negative Breast Cancer, Gastric Adenocarcinoma, Cholangiocarcinoma, Pancreatic Cancer | 11/21 | 02/23 | | |
NCT04731038: Combination Therapy for First Line Treatment of Advanced Cervical Cancer |
|
|
| Recruiting | 1 | 20 | RoW | Anlotinib, Toripalimab, Paclitaxel, Cisplatin/ Carboplatin | Ruijin Hospital | Advanced Cervical Cancer | 07/22 | 07/24 | | |
NCT04659733: Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children |
|
|
| Not yet recruiting | 1 | 36 | NA | Anlotinib hydrochloride | Yizhuo Zhang | Sarcoma | 12/22 | 12/22 | | |
NCT04967079: Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients |
|
|
| Completed | 1 | 33 | RoW | Trametinib, Anlotinib | Shanghai Chest Hospital | Non Small Cell Lung Cancer | 07/23 | 03/24 | | |
NCT05559242: Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients |
|
|
| Not yet recruiting | 1 | 30 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Liver Dysfunction | 06/23 | 07/23 | | |
| Recruiting | 1 | 53 | | Anlotinib combined with concurrent chemoradiotherapy | Yili Friendship Hospital; Yili Friendship Hospital, self-funded | cervical cancer | | | | |
NCT05549973: Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 32 | RoW | Anlotinib Hydrochloride Capsule, dexamethasone | Institute of Hematology & Blood Diseases Hospital | Multiple Myeloma | 07/23 | 07/24 | | |
ChiCTR2200057125: A phase II trial to evaluate the efficacy and safety of vemetinib (ifaxa) plus anlotinib hydrochloride (forcovil) in patients with locally advanced or metastatic non-small cell lung cancer who had disease progression after osimertinib (teresha) treatment |
|
|
| Not yet recruiting | 1 | 30 | | Fumetinib mesylate qd+ anlotinib hydrochloride qd | The General Hospital of the People's Liberation Army; The General Hospital of the People's Liberation Army, Fumonertinib mesylate is provided by Shanghai Elis Pharmaceutical Technology Co., Ltd. and Anlotinib Hydrochloride is provided by Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. | non-small cell lung cancer | | | | |
NCT05193604: A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma |
|
|
| Terminated | 1 | 29 | RoW | TQB2858 injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride for injection, Paclitaxel for injection (albumin bound) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Pancreatic Carcinoma | 11/23 | 11/23 | | |
ChiCTR2200061753: Clinical trial of immune checkpoint inhibitor combined with anlotinib in the second-line treatment of refractory extensive-stage small cell lung cancer |
|
|
| Not yet recruiting | 1 | 40 | China | Nivolumab (3 mg/kg intravenously every 2 weeks). Anlotinib 12mg orally, once a day, continuous medication for 2 weeks and 1 week off, that is, a 3-week (21-day) cycle program. ;Paclitaxel 175mg/m2 chemotherapy was given. Once every 3 weeks, follow up after 4-6 consecutive times. | Shanghai Chest Hospital ; Shanghai Chest Hospital, Science and Technology Innovation Program of Shanghai | small cell lung cancer | | | | |
| Recruiting | 1 | 43 | RoW | 1200mg of TQB2928 injection+Anlotinib, 1800mg of TQB2928 injection+Anlotinib | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Osteosarcoma, Other Solid Tumors | 10/25 | 02/26 | | |
NCT06331169: Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer |
|
|
| Not yet recruiting | 1 | 42 | RoW | Anlotinib, Anlotinib dihydrochloride, Trastuzumab deruxtecan, DS-8201 | Fudan University | Breast Cancer | 12/26 | 06/27 | | |
HBCH-RT-2021-01, NCT05021328: Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC |
|
|
| Recruiting | 1 | 20 | RoW | Toripalimab, JS001, Toripalimab Injection, Teruipuli dankang Zhusheye, TuoYI, Anlotinib, AL3818, Anlotinib Hydrochloride Capsules, FuKeWei, SBRT 7Gy✖️5 QD | Hubei Cancer Hospital | NSCLC | 06/24 | 06/25 | | |
ChiCTR2300068691: Pharmacokinetic study of anlotinib hydrochloride capsules in the treatment of relapsed or refractory pediatric sarcoma |
|
|
| Not yet recruiting | 1 | 36 | | Anlotinib | The Children’s Hospital, Zhejiang University School of Medicine; The Children’s Hospital, Zhejiang University School of Medicine, Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Sarcoma | | | | |
NCT05975645: A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC). |
|
|
| Recruiting | 1 | 40 | RoW | Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma | 12/24 | 04/25 | | |
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer. |
|
|
| Recruiting | 1 | 75 | RoW | TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Colorectal Cancer | 03/25 | 07/25 | | |
ChiCTR2300067932: A single-center prospective phase II clinical study of Sindillimab combined with anrotinib and gemcitabine in the treatment of potentially resectable bile duct carcinoma |
|
|
| Recruiting | 1 | 20 | | Sindillimab in combination with androtinib and gemcitabine | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Investigator initiated (self-funded) | cholangiocarcinoma | | | | |
NCT05942508: A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy |
|
|
| Recruiting | 1 | 20 | RoW | TQB2450 Injection + Anlotinib Hydrochloride Capsules | Jinming Yu | Limited Stage Small Cell Lung Cancer, Not Progressed After First-line Chemoradiotherapy | 02/26 | 02/26 | | |
